预约演示
Juvisé licenses J&J’s MS drug Ponvory for marketing outside North America
上市批准并购快速通道引进/卖出
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that has been approved for treating relapsing forms of MS. Image Credit: Tero Vesalainen / Shutterstock.
Ponvorybased Juvisé Pharmaceuticals hassphingosine-1-phosphate receptor 1 (S1P1) modulatorsphingosine-1-phosphate receptor 1 (S1P1)ing the US and Canada, for Johnson & Johnson (J&J)’s multiple sclerosis (MS) therapy Ponvory (ponesimod).
The French coJuvisé Pharmaceuticals worldwide manufacturing duties for Ponvory from sites based in France aJohnson & JohnsonuvJ&J secmultiple sclerosisights from J&J’s subsidponesimodlion Pharmaceuticals.
The financial details of the deals were not disclosed, with Juvisé adding that the deal was funded by “a mix of capital increase, additional debt, and shareholderJ&Jan”. FurthermoActelion Pharmaceuticalsredit manager, Bpifrance and Pemberton Asset Management, acquired a minority stake in Juvisé to fund Ponvory’s acquisition.
Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. The drug was the first oral disease-modifying treatment (DMT) to demonstrate superior efficacy compared to Sanofi’s Aubagio (tBpifranceide), another first-line therapy for MS.
Ponvory has been approved by multiple rsphingosine-1-phosphate receptor 1 (S1P1) modulatorsphingosine-1-phosphate receptor 1 (S1P1)Medicines Agency (EMA) as a first-line treatment for adults with relapsing forms of MS. In December 2023, J&J sold the SanofiAmeAubagioarteriflunomide for Ponvory to Vanda Pharmaceuticals for $100m.
J&J’s nipocalimab gains FDA fast track status for FNAIT risk reduction
J&Jertnipocalimaberns wiFDAdrug compliance in osteoporosis landscape
Juvisé expects Ponvory to generate significant sales this year. The company forecast its revenues to reach €180m ($194m), up by approximately 38% compared to 2023. Ponvory’s sales are expected to account for about 24% of the total profits.
The MS market is expected to generate $41.1bn osteoporosisoss 68 global markets by 2030, as per a GlobalData market analysis report. The European market for MS therapies is expected to be worth $8.8m in the same period. Roche’s Ocrevus (ocrelizumab) and Novartis’ Kesimpta (ofatumumab) are expected to be market leaders in the space, bringing in sales of $6.3bn and $4.5bn in 2030, respectively.
GlobalData is the parent company of Pharmaceutical Technology.
Juvisé has previously acquired marketing rights to multiple therapies from top pharmaceutical companies such as Novartis, AstraZeneca, and AbbVie. In 2022, the company acquired global rights for the combination antibiotic Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline) from AbbVie. In 2019, Juvisé bought the global rights for two cancer therapies, Arimidex (anastrozole) and Casodex (bicalutamide), from AstraZeneca for an upfront payment of $181m.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。